Mobile website
Archive > Volume 25 Issue 4 > 2018,25(4):401-406. DOI:10.3872/j.issn.1007-385X.2018.04.014 Prev Next
Clinical Research
Clinical efficacy of DC-CIK immunotherapy in treatment of advanced pancreatic adenocarcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To analyze and compare the clinical efficacy and safety of dendritic cell cytokine-induced killer cells (DC- CIK) combined with palliative therapy or chemotherapy in the treatment of advanced pancreatic carcinoma. Methods: A retrospective study was carried on 50 patients with advanced pancreatic carcinoma who were hospitalized in department of oncology of Shanxi Dayi Hospital during September 2012 to February 2016. The patients were divided into four groups according to the therapy they received (palliative treatment group, palliative+DC-CIK treatment group, chemotherapy group and chemotherapy+DC-CIK treatment group); the immunological function, quality of life and survival time of patients were analyzed; and the efficacy and safety of DC-CIK cell ther- apy was also evaluated. Results: The percentages of CD8 + T cells and NKT cells in DC-CIK combined therapy groups were significant- ly improved compared with that of pre-treatment, and the percentages of CD3 + , CD8 + , NK, NKT cells were increased compared with control groups (P<0.05). The quality of life of patients was significantly improved (P<0.05), while median PFS and median OS were improved but without statistical significance (P>0.05). Conclusion: Compared with palliative therapy and chemotherapy alone, com- bined DC-CIK immunotherapy can effectively improve the cellular immunity function and quality of life in patients with advanced pan- creatic cancer. However, there was no significant extension in overall survival.
Keywords:
Project Supported:
Project supported by the Biological Treatment Demonstration Platform Project of Shanxi Province (No.2014091105-0101)
Clc Number:
